Biotech News

Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesCommercial

Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027 Shared updated long-term efficacy data for both relutrigine and ulixacaltamide Outlined plans to extend ulixacaltamide into Parkinson’s disease, Restless Legs

Related news

Praxis Precision Medicines

Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies. Ulixacaltamide Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential...

Recent company news

Stock data

Close
310.90 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States